ArticleTheranostics2019
Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.Experimental and molecular pathology · 2026Article
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review).Oncology reports · 2026Review
- Tumor-Associated Macrophage-Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF-κB Pathway.Cancer science · 2026Article
- The Significance of CXCL1 in Cancer: An Overview of Molecular Mechanisms.International journal of molecular sciences · 2026Review
- C-X-C motif chemokine ligand 1 derived from oral squamous cell carcinoma promotes cancer-associated fibroblast differentiation and tumor growth.Molecular biomedicine · 2025Article
- Review
- Identification of Bacterial Lipopolysaccharide-Related Molecular Subtypes and Development of a Four-Gene Prognostic Risk Model in Cervical Cancer.International journal of women's health · 2025Article
- Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.Molecular cancer · 2024Review
- The Clinical Significance and Involvement in Molecular Cancer Processes of Chemokine CXCL1 in Selected Tumors.International journal of molecular sciences · 2024Review
- CXCL1 promotes cell migration in hepatocellular carcinoma by regulating the miR-30b-5p/ICAM-1 axis.Journal of Cancer · 2024Article
- TGFβ1 induces CXCL1 to promote stemness features in lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer.International journal of molecular sciences · 2023Review
- DNA Methylation-Mediated Overexpression ofInternational journal of molecular sciences · 2023Article
- The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin.International journal of molecular sciences · 2022Review
- Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis.Seminars in cancer biology · 2022Review
- The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs.International journal of molecular sciences · 2022Review
- Review
- Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?Frontiers in molecular biosciences · 2022Review
- Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.Cancer immunology, immunotherapy : CII · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Makito MiyakeNara Medical University, Department of Urology, Nara, Japan.
Hideki FuruyaUniversity of Hawaii Cancer Center, Clinical and Translational Research, Honolulu, Hawaii.
Sayuri OnishiNara Medical University, Department of Urology, Nara, Japan.
Kanani HokutanUniversity of Hawaii Cancer Center, Clinical and Translational Research, Honolulu, Hawaii.
Satoshi AnaiNara Medical University, Department of Urology, Nara, Japan.
Owen ChanUniversity of Hawaii Cancer Center, Clinical and Translational Research, Honolulu, Hawaii.
Sixiang ShiDepartment of Radiology, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Kiyohide FujimotoNara Medical University, Department of Urology, Nara, Japan.
Steve GoodisonNonagen Bioscience Corporation, Jacksonville, Florida.
Weibo CaiDepartment of Radiology, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Charles J RosserUniversity of Hawaii Cancer Center, Clinical and Translational Research, Honolulu, Hawaii.
Nara Medical University · JPCancer Center of Hawaii · USUniversity of Wisconsin–Madison · USNonagen Bioscience (United States) · USUniversity of Hawaiʻi at Mānoa · USUniversity of Hawaii Cancer Center
Funding
VALIDATION OF A MULTIPLEXED ASSAY FOR BLADDER CANCER DIAGNOSISR01CA198887 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI ROSSER, CHARLES J · 2016 to 2025
$6.8MDevelopment of molecular assays for non-invasive bladder cancer detectionR44CA173921 · NCI · NONAGEN BIOSCIENCE CORPORATION · PI GOODISON, STEVE · 2013 to 2015
$2.0MNCI NIH HHS R01 CA198887NCI NIH HHS R44 CA173921
Abstract
PubMed holds no abstract for this paper.
Indexed as
Interleukin-6 InhibitorsAnimalsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCell ProliferationChemokine CXCL1Disease Models, AnimalHumansInterleukin-6MaleMiceNeoplasm TransplantationProstatic NeoplasmsTissue Inhibitor of Metalloproteinase-4Tissue Inhibitor of MetalloproteinasesTransplantation, HeterologousAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalChemokine CXCL1CXCL1 protein, humanIL6 protein, humanInterleukin-6Interleukin-6 InhibitorsTissue Inhibitor of Metalloproteinase-4Tissue Inhibitor of Metalloproteinasesbladder cancerCXCL1IL6prostate cancerTIMP4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.